RSLS - reshapelifesciences.com Debt to Book Capitalization Ratio

The expansion of GLP-1 drugs is undermining demand for ReShape Lifesciences (RSLS) bariatric devices, as confirmed by the total debt-to-book capitalization chart on the GURU.Markets platform, where 0.02 represents the current metric value. ReShape Lifesciences (RSLS) aims for leadership in minimally invasive weight correction through the commercialization of banding systems, while simultaneously modernizing Lap-Band smart sensors and infusion mechanisms.

ReShape Lifesciences, Inc. - RSLS Debts to Book Capitalization (period 07/04/2022 - 08/30/2025)

Summary analytical data breakdowns for reshapelifesciences.com (RSLS)

- price and consensus price forecast:

Stock Price ReShape Lifesciences Inc.|RSLS - Average Forecast Price

- market capitalization data:

Market Value ReShape Lifesciences|RSLS - Value Adjusted for Debt and Cash

- book capitalization data:

Book Value per Share ReShape Lifesciences|RSLS - Book Capitalization|Market Value to Book Value Ratio reshapelifesciences.com|RSLS - Total Asset Value of Company

- debt and liquidity data:

Total Debt to Capital ReShape Lifesciences|RSLS - Long-Term Liabilities to Capital|Short-Term Debt to Equity Ratio ReShape Lifesciences Inc.|RSLS - Company Aggregate Debts|Debt to Book Value ReShape Lifesciences

Analysis of all company metrics:RSLS ReShape Lifesciences Inc

Flagship merchandise of ReShape Lifesciences, Inc.

ReShape Lifesciences aims to stabilize its market position amid asset restructuring. By analyzing the debt-to-market cap ratio, investors assess the proportion of debt relative to the total balance sheet value. This metric determines the company's level of dependence on creditors and the sustainability of its financial leverage. For RSLS, this control is critical due to limited liquidity during the merger with a biopharmaceutical partner. The market expects an optimization of the capital structure to mitigate operational risks.

Competitors of ReShape Lifesciences